Table 1. Characteristics of the trials included in the meta-analysis.
| Author, Year | Phase | Age (years) median (range) | Disease stage | Treatment setting | Capecitabine dose | No. of patients for analysis | Number of cycles median (range) | CTCAE version |
|---|---|---|---|---|---|---|---|---|
| Blum, 199918 | II | 56 (26-78) | Metastatic | 2nd or 3rd line | 1,255 mg/m2 bid | 162 | NR | 1 |
| Oshaughnessy, 200119 | II RCT | 69 (54-83) | Locally advanced/ Metastatic | 1st line | 1,255 mg/m2 bid | 61 | 4 | 1 |
| Blum, 200120 | II | 53 (29–77) | Locally advanced/ Metastatic | 2nd or later line | 1,255 mg/m2 bid | 74 | NR | 1 |
| Jakob, 200221 | II | 46 (35-60) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 14 | 5 (1–19) | 1 |
| Talbot, 200222 | II RCT | 52 (33-67) | Locally advanced/ Metastatic | 1st, 2nd or 3rd line | 1,255 mg/m2 bid | 22 | NR | NR |
| Reichardt, 200323 | II | 56 (32–77) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 136 | 4 (1–33) | NR |
| Fumoleau, 200424 | II | 54 (30–80) | Locally advanced/ Metastatic | 2nd or later line | 1,250 mg/m2 bid | 126 | 6 (1–15) | NR |
| Wist, 200425 | II | 55 (35-74) | Locally advanced/ Metastatic | 2nd or later line | 1,250 mg/m2 bid | 48 | NR | 1 |
| Lee, 200426 | II | 48 (31–66) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 38 | 6 (1–15) | 2 |
| Miller, 20056 | III | 52 (30-77) | Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 215 | NR | 2 |
| Bajetta, 200515 | II | 73 (65-89) | Metastatic | 1st or 2nd line | 1,250 mg/m2 bid | 30 | 6 (1-8) | NR |
| 1,000 mg/m2 bid | 43 | 6 (1-8) | ||||||
| El-Helw, 20057 | II | 48 (20–73) | Metastatic | 1st, 2nd or later line | 1,000 mg/m2 bid | 57 | 4 (1-44) | NR |
| Cameron, 200827 | II | 51 (28–83) | Locally advanced/ Metastatic | 2nd or later line | 1,250 mg/m2 bid | 191 | NR | 3 |
| Rossi, 200716 | II | 62 (38-87) | Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 7 | 9 (1-35) | NR |
| 1,000 mg/m2 bid | 30 | |||||||
| von Minckwitz, 200928 | III | 59 (33-82) | Locally advanced/ Metastatic | 1st or 2nd line | 1,250 mg/m2 bid | 78 | 6 (1-42) | 2 |
| Muss, 200929 | III | >=65 | Stage I to IIIB | Adjuvant | 1,000 mg/m2 bid | 299 | 6 | 3 |
| Hortobagyi, 201030 | III | 52 (25–79) | Locally advanced/ Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 368 | 4 (1-33) | 3 |
| Sparano, 201031 | III | 53 (24-81) | Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 603 | 5 (1-50) | 3 |
| Kaufmann, 201032 | II | 65 (37–90) | Metastatic | 1st line | 1,000 mg/m2 bid | 161 | 7 | 2 |
| Clemons, 201033 | II RCT | 54 (31-74) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 43 | 3 (1-19) | 3 |
| Robert, 201134 | III | 57 (23-88) | Metastatic | 1st line | 1,000 mg/m2 bid | 201 | 9 | NR |
| Pallis, 20125 | III | 60 (34–82) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 74 | 6 (1–15) | 3 |
| Stockler, 201135 | III | 62 | Locally advanced/ Metastatic | 1st line | 1,000 mg/m2 bid | 107 | 12 | 2 |
| Baselga, 20128 | II RCT | 54 | Locally advanced/ Metastatic | 1st or 2nd line | 1,000 mg/m2 bid | 112 | 7 | 3 |
| Huang, 201236 | II | 50 (26–71) | Metastatic | 1st, 2nd or later line | 1,000 mg/m2 bid | 64 | 4 (1–20) | 3 |
| Goldstein, 201313 | II RCT | 57 (31-80) | Metastatic | 1st line | 1,000 mg/m2 bid | 66 | 7 | NR |
| Crown, 201337 | III | 54 (31-77) | Metastatic | 2nd or later line | 1,250 mg/m2 bid | 215 | 6 (1-47) | 3 |
| Arowolo, 201338 | II | 50 (32–70) | Locally advanced | Neoadjuvant | 1,000 mg/m2 bid | 16 | (3-8) | 2 |
| Tolaney, 201439 | II | 53 (29–71) | Early stage operable | Neoadjuvant | 1,000 mg/m2 bid | 24 | 4 | NR |
| Mita, 201440 | II RCT | 54 (39-69) | Locally advanced/ Metastatic | 2nd line | 1,250 mg/m2 bid | 14 | NR | 3 |
| Smorenburg, 201441 | III | 75 (65–86) | Metastatic | 1st line | 1,000 mg/m2 bid | 38 | 7 (1–8) | 3 |
| Kaufman, 201542 | III | 53 (26-80) | Locally advanced/ Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 546 | 5 (1-61) | 3 |
| Martín, 201543 | II RCT | 61 (34–87) | Metastatic | 1st, 2nd or later line | 1,250 mg/m2 bid | 95 | NR | NR |
| Lee, 201514 | III | 48 | Stage I to IIIB | Adjuvant | 1,250 mg/m2 bid | 455 | NR | NR |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; NR, not reported; RCT, Randomized Controlled Trial